Abstract
Background We aimed at estimating the risk of venous thromboembolism (VTE), thrombocytopenia (TCP), and VTE associated with TCP, by age and sex, after the first dose of both adenovirus vector-based and mRNA-based Covid-19 vaccines, and after the second dose of m-RNA vaccines.
Methods In this population-based retrospective cohort study in the national health care databases in Catalonia, we examined three groups: 1 662 719 people 10 years of age and over vaccinated with the first dose of a Covid-19 vaccine, 622 778 with the second dose, and 190 616 diagnosed of Covid-19 in the same period (between1 January 2021 and 18 April 2021). The rates of various clinical presentations of VTE and TCP were compared with those in the reference population (7 013 040 people served by the health care system in 2019). The two primary outcomes were the observed 21 day rate of a composite variable of cerebral venous sinus thrombosis, mesenteric thrombosis, portal vein thrombosis, or any venous thromboembolism (VTE) associated with thrombocytopenia (TCP), and the rate of any VTE associated with TCP (VTE+TCP). Analyses were standardised by age and sex.
Results The 21 day rate per 100 000 of the primary composite variable was 2.15 in the reference population, 5.65 following the first vaccine dose (standardised difference, 2.53 (95% CI [CI], 1.04 to 4.00), and 7.23 following the second dose (standardised difference, 4.07 (95% CI, 1.43 to 6.70). The event rates of VTE+TCP and of all the secondary variables showed the same patterns.
Excess event rates were higher in men than in women, and they were not especially increased in any particular age group. All Covid-19 vaccines were associated with increased rates of the outcome variables.
Excess event rates were much higher in the Covid-19 cohort (35.60 per 100 000 (95% CI, 26.15 to 45.06).
Conclusions We observed increases of rates of venous thromboembolism in usual and unusual anatomical sites and of thrombocytopenia in recipients of both adenovirus vector and mRNA vaccines against Covid-19. Excess rates were higher in men than in women and they were not particularly elevated in any specific age group.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
For reasons of public health emergency, the study protocol was deposited in the registry of the Ethics Committee which evaluated and approved the protocol. The protocol was published at the institutional web of the Catalan Institute of Pharmacology: https://www.icf.uab.cat/es/download/enllac/assets/pdf/Research%20Protocol%20-%20Covid-19%20vaccines%20and%20thromboembolism%20and%20thrombocytopenia.pdf
Clinical Protocols
Funding Statement
There was no direct funding of this study. The institutions of the Department of Health where the authors work were not involved in the study design; in the analysis, and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. All authors had full access to all of the data (including statistical reports and tables) in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Research Ethics Committee of HU Vall Hebron, Institut Catala de la Salut, Barcelona (protocol reference number EOM(AG)051/2021(5870).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of interests statement All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.
Role of the funding source There was no direct funding of this study. The institutions of the Department of Health where the authors work were not involved in the study design; in the analysis, and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. All authors had full access to all of the data (including statistical reports and tables) in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis.
Study protocol
Data sharing Owing to Spanish data protection regulations, individual patients’ data can be used by health authorities and public health institutions in situations of exceptional relevance for public health. However, these data cannot be shared with third parties. The CMDB provided the results of the analyses as anonimised .xls files, which were archived. Detailed aggregated data are provided in the Supplementary Material of this article. All aggregated data will be available upon reasonable request to the corresponding autor.
ecomaredon{at}gencat.cat
ffinaaviles{at}gencat.cat
lgarciaeroles{at}catsalut.cat
xvg{at}icf.uab.cat
mmedinap{at}gencat.cat
Spelling errors have been corrected in the Summary (5th line, year 2019), missing axis labels have been added to figure S1. Details in calculation of background incidence have been added to the Methods section. 172 recipients of a second dose of VaxZevria have been deleted from tables 2 and S13. A sentence in the Discussion regarding the risk of mesenteric thrombosis with Spikevax has been corrected. A spelling error on the number of cases of unusual site VTE or VTE+TCP in the Results section has been corrected.
Data Availability
Owing to Spanish data protection regulations, individual patients data can be used by health authorities and public health institutions in situations of exceptional relevance for public health. However, these data cannot be shared with third parties. The CMDB provided the results of the analyses as anonimised .xls files, which were archived. Detailed aggregated data are provided in the Supplementary Material of this article. All aggregated data will be available upon reasonable request to the corresponding autor after peer reviewed publication.
